Report : North America PCR for Respiratory Infection Diagnostics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Real-Time PCR (qPCR), Multiplex PCR, Traditional PCR, Digital PCR, Reverse-Transcriptase (RT-PCR), and Others), Product Type (Reagents & Kits, Instruments, and Others), Infection Type (Bacterial Infections, Viral Infections, and Fungal & Other Pathogens), and End User (Hospitals, Physician Clinics, Clinical Laboratories, Academic & Research Institutions, Biotech & Pharma Companies, and Others)
The real-time PCR (qPCR) segment by type is estimated to lead the market growth during the forecast period.
According to a new market research study of “North America PCR for Respiratory Infection Diagnostics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Type, Product Type, Infection Type, End User and Country.” The North America PCR for respiratory infection diagnostics market is expected to reach US$ 3,581.63 million by 2028 from US$ 1,766.10 million in 2021; it is estimated to grow at a CAGR of 10.6% from 2021 to 2028. The report highlights trends prevailing in the North America PCR for respiratory infection diagnostics market and the factors driving market along with those that act as hindrances. The growth of the market is determined due to some of the key driving factors, such as increasing burden of chronic respiratory diseases (CRDs) and growing developments in PCR testing, are expected to propel the growth of the market. However, availability of alternative assays is the major factor hindering the market growth.
Chronic respiratory diseases (CRDs) are among the leading causes of morbidity globally due to the heavy consumption of tobacco. For instance, according to the WHO, in 2018, the fourth largest cause of mortality in the US was chronic lower respiratory illness, predominantly COPD. Nearly 15.7 million Americans (6.4%) have been diagnosed with COPD. The burden of CRDs is expected to increase in the future due to poor air quality, increase in addiction to smoking, and rise in geriatric population that is more prone to COPD and lung cancer. Moreover, programs initiated in the countries to improve treatment and support the people living with respiratory diseases are likely to increase the demand for PCR for the diagnosis of respiratory diseases. This will lead to the market growth during the forecast period. The demand for PCR testing to diagnose infectious diseases has significantly risen in the past few years. The growing technological advancements have added an extra advantage of point-of-care testing through PCR, which has surged the demand for PCR diagnostics. In addition, the demand has exponentially raised due to the outbreak of COVID-19. Since the pandemic has initiated, reverse transcription-polymerase reaction (RT-PCR) test has been preferably used to diagnose and examine the genetic material of SARS-CoV-2 RNA. The RT-PCR method is widely accepted as the gold standard for the detection of SARS-CoV-2 RNA due to its sensitive testing. Therefore, considering the demand for PCR testing, various market players have introduced PCR products and entered strategic developments in the global market. Also, most companies are now offering real-time polymerase chain reaction (PCR) tests for COVID-19, which is contributing to the growth of the target market.
COVID-19 pandemic has served vital growth opportunities for the PCR for respiratory infection diagnostics market. The market has experienced exponential growth during the pandemic due to tremendous demand for COVID-19 testing through PCR. North America is the leading market that has significantly contributed to the growth of the market. There have been various factors, including increased incidences of COVID-19 positive patients, growth in PCR technologies, increasing production of reagents and kits, and many other factors. The cases majorly led to the demand for PCR testing in the countries such as the US, Canada, and Mexico. In addition, companies such as Omega Laboratories and LaunchWorks are launching various PCR testing in countries expanding the services, due to increasing demand from governments, communities, and organizations to track and control the spread of the virus.
The North America PCR for respiratory infection diagnostics market, by type, is segmented into real time PCR (qPCR), traditional PCR, reverse-transcriptase (RT-PCR), digital PCR, multiplex PCR, and others. Based on product type, the North America PCR for respiratory infection diagnostics market is segmented into reagents and kits, instruments, and others. Based on infection type, the North America PCR for respiratory infection diagnostics market is segmented into bacterial infection, viral infection, and fungal & other pathogens. The bacterial infection segment is further divided into bordetella, streptococcus pneumoniae, staphylococcus aureus, haemophilus influenzae, moraxella catarrhalis, mycoplasma pneumoniae, chlamydophila pneumoniae, legionella and others. Additionally, the viral infection segment is further bifurcated into rhinoviruses, influenza virus, severe acute respiratory syndrome (sars) cov-2 virus, respiratory syncytial virus (rsv), adenovirus, enterovirus, parainfluenza, human metapneumovirus (hmpv) and others. Futher, based on end user, the North America PCR for respiratory infection diagnostics market is segmented into hospitals, physician clinics, clinical laboratories, academic and research institutions, biotech and pharma companies, and others. Geographically, the North America PCR for respiratory infection diagnostics market can be segmented into U.S, Mexico and Canada.
Abbott, F. HOFFMANN-LA ROCHE LTD, Hologic, Inc., BD, BIO-RAD LABORATORIES INC., bioMerieux SA, QIAGEN, Thermo Fisher Scientific Inc. and Seegene Incare among the leading companies operating in the North America PCR for respiratory infection diagnostics market.
Contact Person: Sameer Joshi
Email Id: firstname.lastname@example.org